Autonomously Bioluminescent Mammalian Cells for Continuous and Real-time Monitoring of Cytotoxicity

Summary

Mammalian cells expressing the bacterial bioluminescence gene cassette (lux) produce light autonomously. The resulting bioluminescent dynamics upon chemical exposure have been demonstrated to reflect the treatment effects on cellular growth and metabolism, making these cells an inexpensive, continuous, real-time toxicity screening tool that can easily be adapted for high-throughput automation.

Abstract

Mammalian cell-based in vitro assays have been widely employed as alternatives to animal testing for toxicological studies but have been limited due to the high monetary and time costs of parallel sample preparation that are necessitated due to the destructive nature of firefly luciferase-based screening methods. This video describes the utilization of autonomously bioluminescent mammalian cells, which do not require the destructive addition of a luciferin substrate, as an inexpensive and facile method for monitoring the cytotoxic effects of a compound of interest. Mammalian cells stably expressing the full bacterial bioluminescence (luxCDABEfrp) gene cassette autonomously produce an optical signal that peaks at 490 nm without the addition of an expensive and possibly interfering luciferin substrate, excitation by an external energy source, or destruction of the sample that is traditionally performed during optical imaging procedures. This independence from external stimulation places the burden for maintaining the bioluminescent reaction solely on the cell, meaning that the resultant signal is only detected during active metabolism. This characteristic makes the lux-expressing cell line an excellent candidate for use as a biosentinel against cytotoxic effects because changes in bioluminescent production are indicative of adverse effects on cellular growth and metabolism. Similarly, the autonomous nature and lack of required sample destruction permits repeated imaging of the same sample in real-time throughout the period of toxicant exposure and can be performed across multiple samples using existing imaging equipment in an automated fashion.

Introduction

In the U.S., pharmaceuticals and other products intended for human consumption require extensive assessment before they are approved for consumer use by the Food and Drug Administration. The financial burden for performing this testing is placed on the developer¹, which substantially increases the cost of new compound development and therefore translates into an increased cost for consumers. While traditionally much of this screening has utilized animal subjects to act as proxies for human hosts, this has proven to be a large financial burden, with an estimated $2.8 billion spent annually on ADME/Tox (adsorption, distribution, metabolism, excretion, and toxicity) screening alone² and mounting evidence suggesting that animal models cannot reliably predict human toxicological responses³. Therefore, in vitro human cell culture-based testing has gained popularity over the past two decades because of its relatively lower cost, higher throughput, and better representation of human bioavailability and toxicology⁴. Current cell culture-based toxicity screening methods employ various endpoints, such as the measurement of ATP levels, screening the activity of endogenously available cytoplasmic enzymes, probing the integrity of the cellular membrane, or tracking the level of mitochondrial activity, to evaluate cellular viability^5,6. However, regardless of the endpoint chosen, these methods all require the destruction of the sample before measurements can be taken, thus only producing data at a single time point. As a result, large numbers of samples need to be prepared and treated in parallel for basic toxicological kinetics studies, again adding to the cost and labor required for new compound development. Alternatively, assays using secreted luciferase such as Gaussia luciferase⁷, Vargula luciferase⁸, and Metridia luciferase⁹ have been developed that eliminate the need for cell lysis and require a fraction of the media for endpoint measurement, however, these are still limited to sampling at predetermined time points and also require the addition of exogenous light-activating substrates.

To avoid the detriment of requisite sample destruction as well as to eliminate the cost of substrates, a human cell line has been engineered that expresses the full bacterial bioluminescence (lux) gene cassette (luxCDABEfrp) to allow for continuous monitoring of live cells that is similar to fluorescent-dye based live cell imaging, but without the additional photon-activating and microscopic investigation procedures. This cell line is capable of constitutively producing an optical signal for continuous, direct detection without the need for external stimulation, thus avoiding destruction of the sample. Mechanistically, the bioluminescent signal generated from these cells results when the luxAB-formed luciferase enzyme catalyzes the oxidation of a long chain fatty aldehyde (synthesized and regenerated by the luxCDE gene products using endogenous substrates) in the presence of reduced riboflavin phosphate (FMNH₂, which is recycled from FMN by the frp gene product) and molecular oxygen¹⁰. Expression of the lux cassette in the host cell therefore enables light to be produced and detected without cellular destruction or exogenous substrate addition. Similarly, the interaction between the lux genes and the endogenously available FMN, and O₂ cosubstrates, and the requirement for maintenance of an environment that can support the conversion of FMN to FMNH₂, ensures that the resulting bioluminescent signal can only be detected from living, metabolically active cells.

These requirements have previously been exploited to demonstrate that lux-based bioluminescent output correlates strongly with cellular population size¹¹ and that toxic compound exposure impairs autobioluminescent production in a dose-response fashion¹². Here we use a previously characterized autobioluminescent human embryonic kidney (HEK293) cell line¹¹ to demonstrate the automated toxicological screening of an antibiotic of the bleomycin family with known DNA damaging activity as a representative example to validate the application of autobioluminescent mammalian cells for toxicity testing.

Protocol

1. Cell Preparation

1. Recover a vial of bioluminescent HEK293 cells from liquid nitrogen frozen stock and grow them in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 0.01 mM nonessential amino acids, 1x antibiotic-antimycotic, and 0.01 mM sodium pyruvate in a T₇₅ tissue culture flask at 37 °C and 5% CO₂.
   Note: The media and supplemental components will vary based on cell lines and therefore should be chosen accordingly.
2. Refresh medium every 2-3 days until reaching ~80% confluence.
   Note: The amount of cells required will be based on the experimental design. If needed, more cells can be obtained by subculturing.
3. Harvest cells for testing.
   1. Remove the medium and wash the cells with phosphate buffered saline (PBS) by gently swirling the flask and then discarding the spent PBS.
   2. Add trypsin and incubate at 37 °C for 2 min, or until the cells have detached from the flask.
   3. Collect the detached cells in PBS and transfer them into a clean centrifuge tube.
      Note: If nonadherent cell lines are used, separate cells by centrifugation and wash once with PBS.
4. Determine the total cell count using a hemacytometer or other cell counting system.
5. Centrifuge the cell suspension at 300 x g for 5 min. Discard the supernatant and resuspend the cells in fresh, prewarmed medium.
6. Seed equal numbers of cells into individual wells of an opaque multi-well plate. In this example, plate 5 x 10⁵ cells in a 1 ml volume into each well of a black 24-well plate. Plate an equal volume of medium in triplicate wells to act as the negative control.
   Note: The number of cells plated in each well is flexible and can be optimized for individual experiments. For each bioluminescent cell line, experimentally determine the relationship between cell number and bioluminescent output, as well as the minimal detectable cell count prior to any toxicity tests. To do this, measure bioluminescence across a wide range of population sizes (for example, 1 x 10³ to 1 x 10⁶ cells) under standardized imaging conditions.
7. Treat cells with testing compound(s) as described below.

2. Chemical Preparation

1. Prepare the chemical being tested as a concentrated stock solution. In this example, use a 100 mg/ml stock solution of an antibiotic of the bleomycin family.
   Note: To minimize potential vehicle-based toxic effects, especially if an organic solvent is used as a vehicle for chemical addition, it is recommended that the stock concentration be at least 1,000 times the desired post-application concentration.
2. Add the prepared chemical stock directly to the cells. In this example, dose the antibiotic of interest at final concentrations of 100, 200, 300, and 400 μg/ml in triplicate wells. Leave three wells of cells untreated as controls.
   Note: The final concentration of the target chemical should be selected based on specific experimental goals. A wide range of concentrations is normally tested to obtain a full spectrum of the toxic effects.

3. Imaging and Data Analysis

1. Immediately following chemical addition, place the plate in the imaging chamber of appropriate instrument for image acquisition and bioluminescence measurement.
2. Measure bioluminescence every 15 min over a 24 hr period using a 10 min integration time for each reading.
   Note: The integration time used in this example is on a per-plate basis and can be adjusted for measurement on a per-well basis using other luminometers of choice. The integration time can also be adjusted based on the chosen bioluminescent cell line. Because bioluminescence is produced autonomously without cell destruction or any external stimulation, readings can be taken at any desired time point to fulfill specific experimental objectives.
3. Quantify the bioluminescent intensity from each well by identifying a region of interest using compatible software. Display the light output either as the total flux (photons/second) or the average radiance (photons/second/cm²/steridian) of each sample.

Results

In this study, the dynamics of autobioluminescent HEK293 cells were monitored continuously over a 24 hr period in response to antibiotic exposure (Figure 1). The toxic effects of this antibiotic, which is a member of the bleomycin family known to kill living cells by binding to and cleaving DNA¹³, were demonstrated via a decrease in bioluminescent production compared to untreated cells, which can be directly visualized through the pseudocolor images (Figure 2). The autobiolumi...

Discussion

This method demonstrates the use of autonomously bioluminescent mammalian cells as an in vitro cytotoxicity screening assay that allows live cells to be continuously monitored over their lifetime. This protocol is flexible and can be modified to accommodate specific experimental conditions as required. For example, the experiment presented here is suitable for tracking acute toxic effects, but can be adapted to assess slow-acting or long term effects by repeatedly imaging at increased time intervals (i.e.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
IVIS Lumina	PerkinElmer		Other IVIS models and PMT-based plate readers can also be used
Living Imaging 2.0	PerkinElmer		Newer updates of this software is available
75 cm2 cell culture treated flasks	Corning	430641
6-well tissue culture-treated plates	Costar	07-200-83
Black 24-well plate	Greiner Bio-One	662174	96- or 384-well plates can be used for higher throughput applications
Phosphate buffered saline	Hyclone	SH30910
Dulbecco's Modified Eagle's Medium (DMEM), phenol red-free	Hyclone	SH30284
Fetal bovine serum	Hyclone	SH3091003
Nonessential amino acids, 100x	Life Technologies	11140050
Antibiotic-antimycotic, 100x	Life Technologies	15240062
Sodium pyruvate, 100mM	Life Technologies	11360070
Zeocin, 100 mg/ml	Life Technologies	R25001
Tripsin, 0.05%	Life Technologies	25300062